News from Boehringer Ingelheim Vetmedica, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jan 15, 2018, 09:53 ET Planos de saúde passam a oferecer novas opções de tratamento para o câncer de pulmão

Em 2 de janeiro entrou em vigor a atualização do Rol de Procedimentos e Eventos em Saúde da Agência Nacional de Saúde Suplementar (ANS),...


Jan 10, 2018, 08:05 ET Boehringer Ingelheim's Respimat Inhaler Awarded Arthritis Foundation's Ease of Use Commendation

Boehringer Ingelheim announced today that the Arthritis Foundation recognized Respimat with its Ease of Use Commendation. As defined by the...


Dec 11, 2017, 08:14 ET Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017

2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming...


Dec 04, 2017, 09:50 ET Boehringer Ingelheim Invests $80 Million to Expand Animal Vaccine Manufacturing Capacity in the U.S.

Boehringer Ingelheim, a leading provider of animal health products for pets and livestock, today announced investments totaling more than $80...


Nov 10, 2017, 16:04 ET Boehringer Ingelheim Presents New Data for Pradaxa® and its Specific Reversal Agent Idarucizumab (Praxbind®) at AHA Scientific Sessions 2017

Boehringer Ingelheim today announced that important sub-analyses from three major trials in anticoagulation care will be presented at the American...


Nov 10, 2017, 08:00 ET Results from six-month lung imaging study showed slowing of fibrotic progression in patients with IPF treated with Ofev® versus placebo

Boehringer Ingelheim today announced results from a descriptive Phase IIIb lung imaging study providing evidence for the first time that Ofev®...


Sep 06, 2017, 08:30 ET Cansaço e tosse na terceira idade podem ser indícios de doença pulmonar grave

Falta de ar, tosse, cansaço constante e dificuldade para realizar atividades são sinais frequentemente negligenciados na terceira idade, já que é...


Aug 27, 2017, 08:45 ET RE-DUAL PCI™ Results Offer Favorable New Safety Data on Pradaxa®

Boehringer Ingelheim today announced that the RE-DUAL PCI™ trial evaluating Pradaxa® (dabigatran etexilate mesylate) dual therapy for people with...


Aug 17, 2017, 14:32 ET Boehringer Ingelheim anuncia resultados positivos em todas as unidades de negócios

A Boehringer Ingelheim, uma das 20 maiores empresas farmacêuticas do mundo, com foco em pesquisa e inovação, anuncia mais um semestre fiscal...


Aug 15, 2017, 17:30 ET Agente reversor de anticoagulante oral é utilizado pela primeira vez no Brasil após aprovação regulatória, confirmando eficácia e segurança do medicamento

Em abril deste ano, a Boehringer Ingelheim, uma das 20 maiores farmacêuticas do mundo, anunciou a aprovação de Praxbind® (idarucizumabe) pela...


Jul 25, 2017, 08:00 ET The Maker of NexGard® (afoxolaner) and North Shore Animal League America are Celebrating the Dog Days of Summer on "DOGust the 1st" With a Mobile Pet Adoption Event

In celebration of DOGust the 1st-- the universal birthday for shelter and rescue dogs, since most often their actual dates of birth are...


Jul 21, 2017, 15:14 ET Boehringer Ingelheim Breaks Ground on $217 Million Expansion of Fremont, California Manufacturing Facility

Boehringer Ingelheim announced a $217 million investment to upgrade and expand their Fremont manufacturing facility. This investment will bring...


Jun 21, 2017, 08:00 ET Cat's Out of the Bag! The PUREVAX® Team Announces Multi-City Cat Café Tour and Sponsored Cat Adoptions for Adopt-a-Cat Month

Though veterinarians recommend vaccinating cats to help them develop immunity against a number of diseases, many go unvaccinated. In fact,...


May 03, 2017, 18:09 ET Anvisa aprova agente reversor de anticoagulante oral que traz maior tranquilidade para pacientes em caso de emergências

A Boehringer Ingelheim anuncia a aprovação pela ANVISA do Praxbind® (idarucizumabe), indicado para pacientes tratados com o anticoagulante oral...


Mar 30, 2017, 08:00 ET Novozymes and Boehringer Ingelheim announce Strategic Collaboration in Probiotics for Poultry Hatcheries

Boehringer Ingelheim Animal Health and Novozymes today announced a strategic collaboration to develop and commercialize probiotics for global...


Mar 28, 2017, 08:00 ET Yankees Baseball Legend Bernie Williams Raises Awareness of Devastating Lung Disease - IPF - in Honor of his Dad

New York Yankees all-time great Bernie Williams is teaming up with Boehringer Ingelheim to raise awareness of a lung disease called idiopathic...


Jan 18, 2017, 09:00 ET Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review

Boehringer Ingelheim announced today that BI 695501, its adalimumab biosimilar candidate to Humira®*, has been accepted for regulatory review by...


Dec 06, 2016, 06:42 ET Novo medicamento da Boehringer Ingelheim para câncer de pulmão bloqueia de forma irreversível a multiplicação das células cancerígenas

A Boehringer Ingelheim, uma das principais farmacêuticas do mundo focada em pesquisa para soluções terapêuticas inovadoras, lança no Brasil o...


Oct 26, 2016, 08:00 ET Boehringer Ingelheim's adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study

Boehringer Ingelheim today announced top-line results from the pivotal Phase III clinical study of BI 695501, a biosimilar candidate to...


Oct 24, 2016, 08:00 ET Efficacy of Ofev® (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST

At CHEST 2016, two post-hoc pooled analyses of the Phase III INPULSIS® trials were presented that further demonstrate the efficacy of Ofev®...


Oct 09, 2016, 08:05 ET Overall survival data from LUX-Lung 7 head-to-head trial of Gilotrif® (afatinib) versus Iressa® (gefitinib) presented at ESMO

Boehringer Ingelheim today announced results from the LUX-Lung 7 trial that directly compared the efficacy and safety of second-generation...


Sep 28, 2016, 08:00 ET Boehringer Ingelheim boosts immune-oncology pipeline through collaboration with ViraTherapeutics

 Boehringer Ingelheim and ViraTherapeutics today announced a long-term collaboration to jointly develop a next generation oncolytic virus...


Sep 27, 2016, 08:30 ET Boehringer Ingelheim Named to the 2016 Working Mother 100 Best Companies List

Boehringer Ingelheim announced today that it has been named to Working Mother magazine's annual 100 Best Companies list for the fifth consecutive...


Jun 02, 2016, 08:00 ET Boehringer Ingelheim launches ambitious ELUXA trial program to broadly investigate promising lung cancer compound olmutinib

 Boehringer Ingelheim has initiated the ELUXA trial program, designed to further investigate the therapeutic potential of olmutinib (BI...


Feb 29, 2016, 15:25 ET Boehringer Ingelheim lança medicamento inédito para doença rara e revoluciona panorama de tratamento da Fibrose Pulmonar Idiopática

 A Boehringer Ingelheim, uma das 20 principais farmacêuticas do mundo, anuncia o lançamento de OFEV® (nintedanibe) no Brasil,...